Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


Advances in B-Cell Lymphomas: Understanding Current Treatment Approaches

In this podcast episode, listen to Julie M. Vose, MD, MBA; Brad S. Kahl, MD; and John P. Leonard, MD, discuss current and emerging treatment approaches for patients with B-cell lymphomas from a recent satellite symposium at the annual Hematology meeting in 2021.
Brad S. Kahl, MD
John P. Leonard, MD
Julie M. Vose, MD, MBA
Released: February 25, 2022

In this episode, Julie M. Vose, MD, MBA; Brad S. Kahl, MD; and John P. Leonard, MD, discuss treatment approaches for patients with B-cell lymphomas, including information on:

  • Follicular lymphoma
  • Marginal zone lymphoma
  • Mantle cell lymphoma
  • Diffuse large B-cell lymphoma
  • Posttransplant lymphoproliferative disorder

Information on this Educational Activity


Brad S. Kahl, MD

Professor of Medicine
Department of Medical Oncology
Washington University School of Medicine
St Louis, Missouri

Brad S. Kahl, MD, has disclosed that he has received funds for research support from AbbVie, ADCT, AstraZeneca, BeiGene, and Genentech and consulting fees from AbbVie, Adaptive, ADCT, AstraZeneca, Bayer, BeiGene, Bristol-Myers Squibb, Celgene, Genentech, Incyte, Janssen, Karyopharm, Kite, MEI, Pharmacyclics, Roche, and Teva.
John P. Leonard, MD

Richard T. Silver Distinguished Professor of Hematology and Medical Oncology
Professor of Medicine
Weill Cornell Medicine
New York Presbyterian Hospital
New York, New York

John P. Leonard, MD, has disclosed that he has received funds for research support from Genentech and consulting fees from AbbVie, AstraZeneca, Bayer, Bristol-Myers Squibb/Celgene, Epizyme, Genentech/Roche, Genmab, Gilead Sciences/Kite, Incyte, Janssen, Karyopharm, MEI Pharma, Miltenyi, Regeneron, and Sutro.
Julie M. Vose, MD, MBA

Chief, Division of Oncology and Hematology
Neumann M. and Mildred E. Harris Professor
Department of Internal Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Julie M. Vose, MD, MBA, has disclosed that she has received funds for research support from Acerta/AstraZeneca, Celgene/Bristol-Myers Squibb, Epizyme, Incyte, Kite, Loxo, Novartis, and Seattle Genetics and consulting fees from AbbVie, Acerta/AstraZeneca, Conjupro, Janssen/Pharmacyclics, Johnson & Johnson, Kite, Morphosis, Oncternal, Roche/Genentech, and Vaniam Group.

Program Medium

This program has been made available online.


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Atara Biotherapeutics, Inc.
Bayer HealthCare Pharmaceuticals Inc.
BeiGene, Ltd.
Genentech, a member of the Roche Group
Genmab US, Inc.
Incyte Corporation
Karyopharm Therapeutics
Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.

Related Content

Downloadable slideset with highlights from key hematologic cancers as presented at EHA 2022 Congress, from Clinical Care Options (CCO)

Stéphane de Botton, MD Jesús F. San-Miguel, MD, PhD Alessandra Tedeschi, MD Released: June 30, 2022

Experts discuss important new data from ASCO 2022 that may impact treatment for chronic lymphocytic leukemia and mantle cell lymphoma, from Clinical Care Options (CCO)

Brad S. Kahl, MD Anthony Mato, MD, MSCE Released: June 30, 2022

From Clinical Care Options (CCO), download slides reviewing the integration of CAR T-cell therapy into community care

Jesús G. Berdeja, MD Caron A. Jacobson, MD Released: June 30, 2022

Slides from Clinical Care Options (CCO) with key findings on BTK inhibitors in CLL and MCL from the 2022 ASCO, EHA, Pan Pacific, ESMO, and SOHO meetings

Released: June 27, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings